ArticleBMC endocrine disorders2026
Metabolic phenotype stratification identifies patients at high risk of poor glycemic control in type 2 diabetes mellitus: Insights into hepatic metabolic dysfunction.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo characterize metabolic dphenotypes based on integrated hepatic and metabolic indicators and evaluate their association with poor glycemic control in patients with Type 2 diabetes mellitus (T2DM).
methodsA total of 320 patients with T2DM were retrospectively enrolled. Data on liver function, blood lipids, insulin resistance, and indicators related to fatty liver were collected. Unsupervised clustering analysis was performed to construct integrated metabolic risk profiles, and glycemic control levels were compared among different groups. Spearman correlation analysis was used to evaluate associations between hepatic metabolic indicators and glycated hemoglobin (HbA1c). Multivariate logistic regression analysis was conducted to identify independent risk factors for poorly controlled blood glucose. Multicollinearity among independent variables was assessed using variance inflation factors (VIF), with VIF < 5 considered indicative of acceptable collinearity. Predictive performance of the models was assessed using receiver operating characteristic (ROC) curves.
resultsTwo metabolic risk profiles were identified, characterized by differences in hepatic enzyme levels, lipid metabolism, and insulin resistance. Patients in the high hepatic metabolic burden group (Cluster 2) exhibited significantly higher HbA1c levels and a greater incidence of poor glycemic control. HbA1c was positively correlated with alanine aminotransferase (ALT), aspartate aminotransferase (AST), severity of fatty liver, and homeostasis model assessment of insulin resistance (HOMA-IR), but negatively correlated with high-density lipoprotein cholesterol (HDL-C). Multivariate analysis revealed that longer diabetes duration, elevated AST and TG levels, higher HOMA-IR, and metabolic phenotypes classification (Cluster 2) were independent risk factors for poorly controlled blood glucose. The combined predictive model achieved an area under the ROC curve (AUC) of 0.943.
conclusionMetabolic phenotype stratification based on integrated hepatic and metabolic indicators may facilitate identification of T2DM patients at increased risk of poor glycemic control and provide additional information for metabolic risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.